Marker Therapeutics Inc. has published a document discussing the effects of lymphodepletion on Multi-Antigen Recognizing $(MAR)$-T cells in patients with lymphoma. The document highlights that lymphodepletion enhances the expansion and persistence of MT-601 T cell clones, as shown by preliminary data from the Phase 1 APOLLO study. The data suggest that participants undergoing lymphodepletion exhibit significantly higher levels of MAR-T cell clone expansion compared to those who did not. The full document can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marker Therapeutics Inc. published the original content used to generate this news brief on May 20, 2025, and is solely responsible for the information contained therein.